Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicine company that is transforming the drug discovery process.

Relay Therapeutics develops precision medicines using computational modeling, machine learning, molecular simulations, and experimental biology. Its Dynamo platform studies how proteins move and function to identify potential drug-binding sites, discover promising compounds, and optimize drug candidates. The company’s pipeline focuses on oncology and genetic diseases, including programs targeting breast cancer, solid tumors, and vascular anomalies.

Recursion Pharmaceuticals

Recursion Pharmaceuticals is a clinical-stage biotechnology company that is revolutionizing the field of drug discovery.

Recursion is a TechBio company that uses AI, machine learning, automated laboratories, and large biological datasets to discover and develop new medicines. Its Recursion OS connects biological experiments, computational analysis, chemistry, and clinical development to identify drug targets and design potential treatments. Its pipeline includes programs in oncology, rare diseases, neuroscience, and other therapeutic areas.

Valo Health

Valo Health is a technology company that is transforming the drug discovery and development process leveraging human-centric data and AI.

Valo Health uses artificial intelligence, human health data, and predictive chemistry to discover and develop new medicines. Its technology analyzes large-scale patient data to identify disease targets and understand biological causes, then combines those insights with computational modeling and laboratory testing to design and evaluate drug candidates. Valo’s work covers areas including cardiovascular, metabolic, renal, neurological, and cancer diseases.

Lantern Pharma

Lantern Pharma is a clinical stage pharmaceutical company that is revolutionizing the field of oncology. They are pioneering the use of Artificial Intelligence, Machine Learning, and genomics to develop targeted cancer therapies.

Lantern Pharma uses artificial intelligence, machine learning, and genomics to develop cancer therapies and improve the drug development process. Its RADR platform analyzes clinical, genomic, molecular, and drug response data to identify biomarkers, predict patient responses, evaluate drug combinations, and guide clinical trial design. The company develops targeted therapies across multiple cancer indications.

Insitro

Insitro is a company that stands at the intersection of human biology and machine learning redefining drug discovery and development.

Insitro is a drug discovery and development company that combines machine learning with large-scale human and cellular data to identify disease targets and design new medicines. Its platform uses AI to study disease biology and develop small molecules, oligonucleotides, and biologics. Insitro also uses automated laboratory systems and clinical data to support drug discovery and therapeutic development.

Owkin

Owkin is a company that uses AI, machine learning, and medical research to accelerate the development of new treatments and therapies.

Owkin builds AI systems that study real-world patient data to uncover how diseases work and how people respond to therapies. Its software finds new drug targets, predicts treatment outcomes, and supports trial design so researchers can decide faster which medicines to advance. By linking hospitals, labs, and drug developers through intelligent agents, it helps turn complex medical data into diagnostics and therapies that reach patients sooner.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered using an Artificial intelligence (AI) engine.

Atomwise uses artificial intelligence to search through massive libraries of small molecules and find drug candidates that can bind to disease targets. Its platform helps research teams choose better compounds earlier, cut down failed experiments, and move promising therapies into preclinical development more quickly and efficiently.